1.Evolving Cancer Classification in the Era of Personalized Medicine: A Primer for Radiologists.
Ailbhe C O'NEILL ; Jyothi P JAGANNATHAN ; Nikhil H RAMAIYA
Korean Journal of Radiology 2017;18(1):6-17
Traditionally tumors were classified based on anatomic location but now specific genetic mutations in cancers are leading to treatment of tumors with molecular targeted therapies. This has led to a paradigm shift in the classification and treatment of cancer. Tumors treated with molecular targeted therapies often show morphological changes rather than change in size and are associated with class specific and drug specific toxicities, different from those encountered with conventional chemotherapeutic agents. It is important for the radiologists to be familiar with the new cancer classification and the various treatment strategies employed, in order to effectively communicate and participate in the multi-disciplinary care. In this paper we will focus on lung cancer as a prototype of the new molecular classification.
Adenocarcinoma
;
Classification*
;
Humans
;
Lung Neoplasms
;
Molecular Targeted Therapy
;
Precision Medicine*
2.Current Concepts in Non-Gastrointestinal Stromal Tumor Soft Tissue Sarcomas: A Primer for Radiologists.
Akshay D BAHETI ; Jyothi P JAGANNATHAN ; Ailbhe O'NEILL ; Harika TIRUMANI ; Sree Harsha TIRUMANI
Korean Journal of Radiology 2017;18(1):94-106
Non-gastrointestinal stromal tumor (GIST) soft tissue sarcomas (STSs) are a heterogeneous group of neoplasms whose classification and management continues to evolve with better understanding of their biologic behavior. The 2013 World Health Organization (WHO) has revised their classification based on new immunohistochemical and cytogenetic data. In this article, we will provide a brief overview of the revised WHO classification of soft tissue tumors, discuss in detail the radiology and management of the two most common adult non-GIST STS, namely liposarcoma and leiomyosarcoma, and review some of the emerging histology-driven targeted therapies in non-GIST STS, focusing on the role of the radiologist.
Adult
;
Classification
;
Cytogenetics
;
Humans
;
Leiomyosarcoma
;
Liposarcoma
;
Sarcoma*
;
World Health Organization
3.Update on Gastrointestinal Stromal Tumors for Radiologists.
Sree Harsha TIRUMANI ; Akshay D BAHETI ; Harika TIRUMANI ; Ailbhe O'NEILL ; Jyothi P JAGANNATHAN
Korean Journal of Radiology 2017;18(1):84-93
The management of gastrointestinal stromal tumors (GISTs) has evolved significantly in the last two decades due to better understanding of their biologic behavior as well as development of molecular targeted therapies. GISTs with exon 11 mutation respond to imatinib whereas GISTs with exon 9 or succinate dehydrogenase subunit mutations do not. Risk stratification models have enabled stratifying GISTs according to risk of recurrence and choosing patients who may benefit from adjuvant therapy. Assessing response to targeted therapies in GIST using conventional response criteria has several potential pitfalls leading to search for alternate response criteria based on changes in tumor attenuation, volume, metabolic and functional parameters. Surveillance of patients with GIST in the adjuvant setting is important for timely detection of recurrences.
Exons
;
Gastrointestinal Stromal Tumors*
;
Humans
;
Imatinib Mesylate
;
Molecular Targeted Therapy
;
Recurrence
;
Succinate Dehydrogenase
4.Molecular Targeted Therapy in Modern Oncology: Imaging Assessment of Treatment Response and Toxicities.
Katherine M KRAJEWSKI ; Marta BRASCHI-AMIRFARZAN ; Pamela J DIPIRO ; Jyothi P JAGANNATHAN ; Atul B SHINAGARE
Korean Journal of Radiology 2017;18(1):28-41
Oncology is a rapidly evolving field with a shift toward personalized cancer treatment. The use of therapies targeted to the molecular features of individual tumors and the tumor microenvironment has become much more common. In this review, anti-angiogenic and other molecular targeted therapies are discussed, with a focus on typical and atypical response patterns and imaging manifestations of drug toxicities.
Drug-Related Side Effects and Adverse Reactions
;
Humans
;
Molecular Targeted Therapy*
;
Receptor, Epidermal Growth Factor
;
Response Evaluation Criteria in Solid Tumors
;
Tumor Microenvironment
;
Vascular Endothelial Growth Factor A
5.Fluid Retention Associated with Imatinib Treatment in Patients with Gastrointestinal Stromal Tumor: Quantitative Radiologic Assessment and Implications for Management.
Kyung Won KIM ; Atul B SHINAGARE ; Katherine M KRAJEWSKI ; Junhee PYO ; Sree Harsha TIRUMANI ; Jyothi P JAGANNATHAN ; Nikhil H RAMAIYA
Korean Journal of Radiology 2015;16(2):304-313
OBJECTIVE: We aimed to describe radiologic signs and time-course of imatinib-associated fluid retention (FR) in patients with gastrointestinal stromal tumor (GIST), and its implications for management. MATERIALS AND METHODS: In this Institutional Review Board-approved, retrospective study of 403 patients with GIST treated with imatinib, 15 patients with imaging findings of FR were identified by screening radiology reports, followed by manual confirmation. Subcutaneous edema, ascites, pleural effusion, and pericardial effusion were graded on a four-point scale on CT scans; total score was the sum of these four scores. RESULTS: The most common radiologic sign of FR was subcutaneous edema (15/15, 100%), followed by ascites (12/15, 80%), pleural effusion (11/15, 73%), and pericardial effusion (6/15, 40%) at the time of maximum FR. Two distinct types of FR were observed: 1) acute/progressive FR, characterized by acute aggravation of FR and rapid improvement after management, 2) intermittent/steady FR, characterized by occasional or persistent mild FR. Acute/progressive FR always occurred early after drug initiation/dose escalation (median 1.9 month, range 0.3-4.0 months), while intermittent/steady FR occurred at any time. Compared to intermittent/steady FR, acute/progressive FR was severe (median score, 5 vs. 2.5, p = 0.002), and often required drug-cessation/dose-reduction. CONCLUSION: Two distinct types (acute/progressive and intermittent/steady FR) of imatinib-associated FR are observed and each type requires different management.
Adult
;
Aged
;
Aged, 80 and over
;
Antineoplastic Agents/*adverse effects/therapeutic use
;
Ascites/pathology/radiography
;
Benzamides/*adverse effects/therapeutic use
;
Echocardiography/methods
;
Edema/pathology/radiography
;
Female
;
Gastrointestinal Stromal Tumors/drug therapy/pathology/*radiography
;
Gastrointestinal Tract/pathology/*radiography
;
Heart Failure/radiography
;
Humans
;
Male
;
Middle Aged
;
Molecular Targeted Therapy/*adverse effects
;
Pericardial Effusion/pathology/radiography
;
Peritoneal Neoplasms/diagnosis/radiography/secondary
;
Piperazines/*adverse effects/therapeutic use
;
Pleural Effusion/pathology/radiography
;
Pyrimidines/*adverse effects/therapeutic use
;
Radiology
;
Retrospective Studies
;
Tomography, X-Ray Computed
6.Diffuse Large B-Cell Lymphoma in the Era of Precision Oncology: How Imaging Is Helpful.
Hina J SHAH ; Abhishek R KERALIYA ; Jyothi P JAGANNATHAN ; Sree Harsha TIRUMANI ; Vikram R LELE ; Pamela J DIPIRO
Korean Journal of Radiology 2017;18(1):54-70
Diffuse large B cell lymphoma (DLBCL) is the most common histological subtype of Non-Hodgkin's lymphoma. As treatments continues to evolve, so do imaging strategies, and positron emission tomography (PET) has emerged as the most important imaging tool to guide oncologists in the diagnosis, staging, response assessment, relapse/recurrence detection,and therapeutic decision making of DLBCL. Other imaging modalities including magnetic resonance imaging (MRI), computed tomography (CT), ultrasound, and conventional radiography are also used in the evaluation of lymphoma. MRI is useful for nervous system and musculoskeletal system involvement and is emerging as a radiation free alternative to PET/CT. This article provides a comprehensive review of both the functional and morphological imaging modalities, available in the management of DLBCL.
B-Lymphocytes*
;
Decision Making
;
Diagnosis
;
Lymphoma
;
Lymphoma, B-Cell*
;
Lymphoma, Non-Hodgkin
;
Magnetic Resonance Imaging
;
Musculoskeletal System
;
Nervous System
;
Positron-Emission Tomography
;
Positron-Emission Tomography and Computed Tomography
;
Radiography
;
Ultrasonography